Will Johnson & Johnson's Coronavirus Vaccine Dominate the Market?

Whether from niche vaccine developers or well-established pharmaceutical giants, over 70 potential coronavirus vaccines are currently undergoing development. Johnson & Johnson (NYSE: JNJ) was one of the first companies to declare that it was working on such a vaccine, and in March the company said it anticipates clinical trials beginning this fall.

However, there already being plenty of competition in this area, will Johnson & Johnson's new vaccine have what it takes to stand out against its dozens of rivals? Let's take a look at what the pharmaceutical giant's candidate has going for it right now.

Image source: Getty Images.

Source Fool.com